Patients with cancer expect to derive a meaningful clinical benefit from anticancer treatments, especially considering that such therapies are associated with adverse events and, often, substantial financial costs. We have evaluated new anticancer agents approved by the FDA in 2015 and 2016 using the ESMO Magnitude of Clinical Benefit Scale and ASCO Value Framework, and conclude that many agents only offer marginal value.
This is a preview of subscription content, log in via an institution to check access.
References
Saltz, L. B. Progress in cancer care: the hope, the hype, and the gap between reality and perception. J. Clin. Oncol. 26, 5020–5021 (2008).
Booth, C. M. & Eisenhauer, E. A. Progression-free survival: meaningful or simply measurable? J. Clin. Oncol. 30, 1030–1033 (2012).
Booth, C. M. & Tannock, I. Reflections on medical oncology: 25 years of clinical trials — where have we come and where are we going? J. Clin. Oncol. 26, 6–8 (2008).
Booth, C. M. et al. Evolution of the randomized controlled trial in oncology over three decades. J. Clin. Oncol. 26, 5458–5464 (2008).
Seruga, B. et al. Absolute benefits of medical therapies in phase III clinical trials for breast and colorectal cancer. Ann. Oncol. 21, 1411–1418 (2010).
Cherny, N. I. et al. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Ann. Oncol. 26, 1547–1573 (2015).
Schnipper, L. E. et al. Updating the American Society of Clinical Oncology value framework: revisions and reflections in response to comments received. J. Clin. Oncol. 34, 2925–2934 (2016).
Del Paggio, J. C. et al. Do contemporary randomized controlled trials meet ESMO thresholds for meaningful clinical benefit? Ann. Oncol. http://dx.doi.org/10.1093/annonc/mdw538 (2016).
Tap, W. D. et al. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. Lancet 388, 488–497 (2016).
Schlumberger, M. et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N. Engl. J. Med. 372, 621–630 (2015).
Truven Health Analytics. RED BOOK: a comprehensive, consistent drug pricing resource. Micromedex http://micromedex.com/products/product-suites/clinical-knowledge/redbook (2017).
Acknowledgements
C.M.B. is supported as the Canada Research Chair in Population Cancer Care.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary information S1 (table)
Clinical benefit of anticancer agents approved by the FDA in 2015–2016 (PDF 228 kb)
PowerPoint slides
Rights and permissions
About this article
Cite this article
Booth, C., Del Paggio, J. Approvals in 2016: questioning the clinical benefit of anticancer therapies. Nat Rev Clin Oncol 14, 135–136 (2017). https://doi.org/10.1038/nrclinonc.2017.18
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2017.18
- Springer Nature Limited
This article is cited by
-
Predictive validity in drug discovery: what it is, why it matters and how to improve it
Nature Reviews Drug Discovery (2022)
-
The Comparative Effectiveness of Innovative Treatments for Cancer (CEIT-Cancer) project: Rationale and design of the database and the collection of evidence available at approval of novel drugs
Trials (2018)
-
Do current approaches to assessing therapy related adverse events align with the needs of long-term cancer patients and survivors?
Cardio-Oncology (2018)
-
To all involved — we have a problem
Nature Reviews Clinical Oncology (2018)
-
Patient-reported outcomes in cancer care — hearing the patient voice at greater volume
Nature Reviews Clinical Oncology (2017)